Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FTO | Q9C0B1 | 1/20 | 0.34 |
| ▸ | CA12 | O43570 | 2/20 | 0.31 |
| ▸ | CA1 | P00915 | 2/20 | 0.31 |
| ▸ | CA2 | P00918 | 2/20 | 0.31 |
| ▸ | CA9 | Q16790 | 2/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5610393 | 0.76 | LPO (0.41) | FTOCA12CA1CA2CA9 | |
| SCHEMBL27635221 | 0.71 | FTO (0.34) | FTOCA12CA1CA2CA9 | |
| SCHEMBL9369949 | 0.71 | CA2 (0.41) | CA12CA1CA2CA9 | |
| SCHEMBL9511194 | 0.71 | CA12 (0.31) | FTOCA12CA1CA2CA9 | |
| SCHEMBL5323928 | 0.69 | FDPS (0.42) | CA12CA1CA2CA9 | |
| SCHEMBL27362278 | 0.67 | — | — | |
| SCHEMBL9372316 | 0.66 | LMNA (0.40) | CA12CA1CA2CA9 | |
| SCHEMBL27362277 | 0.65 | CA2 (0.39) | CA12CA1CA2CA9 | |
| SCHEMBL2502618 | 0.62 | — | — | |
| SCHEMBL18927708 | 0.60 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040006118-A1 | Nf-kb inhibitors | SMITHKLINE BEECHAM CORPORATION | 2004-01-08 | — | — | US | disclosed |
| EP-1328272-A1 | NF-KAPPA-B INHIBITORS | SmithKline Beecham Corporation (US) | 2003-07-23 | — | — | EP | disclosed |
| WO-2002030423-A1 | NF-λB INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 2002-04-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040006118-A1 | Nf-kb inhibitors | NFKBIA, IKBKB, IKBKG | FTO 4559/4885CA12 4868/4885CA1 4861/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.